Measles cases in 2026?
Short Answer
Both the model and the market overwhelmingly agree that measles cases in 2026 will be above 1500, with no compelling evidence of mispricing.
1. Executive Verdict
- Nearly 2,000 measles cases confirmed in the US by late May 2026.
- The US faces high risk of losing measles elimination status.
- A global surge in measles outbreaks is reported across regions.
- Measles cases in 2026 are strongly indicated to exceed current levels.
- Low vaccination coverage and international travel drive outbreak risk.
- Political instability in Sub-Saharan Africa impedes vaccination and reporting.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 4000 | 35.0% | 46.3% | Nearly 2,000 cases confirmed by late May 2026 makes exceeding 4,000 cases highly plausible. |
| Above 6000 | 17.0% | 25.9% | An early high case count and risk of losing measles elimination status suggest accelerated transmission. |
| Above 10000 | 7.0% | 11.8% | Nearly 2,000 cases by late May and global outbreaks suggest a significant increase in cases. |
| Above 8000 | 11.0% | 17.8% | The early baseline and potential for sustained outbreaks make exceeding 8,000 cases less remote. |
| Above 750 | 99.0% | 92.1% | Market higher by 6.9pp |
Current Context
Global measles activity continues to significantly rise in early 2026. Provisional surveillance data covering October 2025 through March 2026 reports substantial outbreaks worldwide [^][^]. Significant case numbers were reported in countries including India (19,705 cases), Yemen (11,354 cases), and Mexico (10,678 cases) [^][^].
Insufficient immunization rates fuel measles outbreaks globally. Global measles immunization with two doses remains below the 95% threshold required to interrupt transmission, contributing to the highest number of global outbreaks seen since 2003, following pandemic-related disruptions [^]. In contrast to this global resurgence, no measles cases have been reported in the United States at this point [^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This market has traded in a sideways pattern, maintaining a high probability for a "YES" outcome throughout its history. The price opened at 92.0% and has fluctuated within a range of 78.0% to 95.0%, currently sitting at 89.0%. A notable movement occurred early in the period when the price dropped from 92.0% to a low of 81.0% on a significant volume of 200 contracts. This spike in volume suggests there was momentary conviction behind the downward move, though the price has since recovered. The overall high probability held by the market is consistent with the provided context detailing a significant global rise in measles cases in early 2026 due to insufficient immunization rates.
The trading volume provides some insight into market conviction. The largest volume surge coincided with the sharpest price drop, indicating a brief but intense period of disagreement with the high probability. Otherwise, volume has been moderate, suggesting a stable consensus. The price range has established an apparent support level around the 78.0% to 81.0% mark, where the price has previously reversed its downward trend. Resistance appears to be at the high of 95.0%.
Overall, the chart reflects a strong and sustained market sentiment that a "YES" resolution is the most probable outcome. Despite some fluctuations, the price has consistently remained in a high range, above 78.0%. This stability suggests that traders largely agree with the outlook presented in reports of substantial measles outbreaks in countries like India, Yemen, and Mexico, and view the conditions for a "YES" outcome as highly likely to be met.
3. Market Data
Contract Snapshot
This market resolves to "Yes" if the total number of measles cases in 2026 is above 4000, and "No" if it is 4000 or fewer, with the outcome verified by the CDC. The market opened on October 15, 2025, and will close the day following the outcome (at 10am ET) or by December 31, 2026, at 11:59pm EST, with projected payouts 1 hour after closing. Insider trading is prohibited for those with material, non-public information or employed by Source Agencies.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 1000 | $1.00 | $0.01 | 99% |
| Above 1250 | $1.00 | $0.01 | 99% |
| Above 500 | $1.00 | $0.01 | 99% |
| Above 750 | $1.00 | $0.01 | 99% |
| Above 3000 | $0.91 | $0.11 | 89% |
| Above 4000 | $0.37 | $0.65 | 35% |
| Above 6000 | $0.17 | $0.86 | 17% |
| Above 8000 | $0.12 | $0.89 | 11% |
| Above 10000 | $0.08 | $0.93 | 7% |
Market Discussion
As of June 4, 2026, the United States has recorded over 2,000 confirmed measles cases, with the CDC reporting 2,030 cases across 40 jurisdictions, placing the nation on track to surpass the 2,288 cases reported in the entirety of 2025, a three-decade high [^][^][^][^][^][^]. Projections for the entire US in 2026 estimate between 5,000 and 7,000 cases nationwide [^]. This increase is primarily attributed to declining vaccination rates below the 95% required for herd immunity, increased global circulation of the virus, and widespread vaccine hesitancy [^][^][^][^][^][^]. Prediction markets reflect these concerns, with one market showing a 91% implied probability that total cases will be "Above 3000" in 2026 [^].
4. What major measles vaccination campaigns or public health interventions are planned by the WHO and Gavi for the remainder of 2026?
| Strategy Period | Including 2026 [^] |
|---|---|
| Key Outbreak Funder | Gavi is a primary funder for measles outbreak response [^] |
| Outbreak Prevention Coverage | Below 95% threshold [^][^] |
WHO and Gavi will prioritize targeted measles vaccination campaigns through 2026. Their joint strategy for this period emphasizes efficient, timely, and targeted preventive campaigns to avert outbreaks and epidemics, alongside intensified responses to existing outbreaks of vaccine-preventable diseases [^]. This strategic framework aligns with the global Immunization Agenda 2030 (IA2030) and the Measles and Rubella Strategic Framework 2021–2030 (MRSF) [^]. The planned interventions include supporting the administration of first and second doses of measles or measles-rubella (MR) vaccines, implementing follow-up campaigns to address existing immunity gaps, and conducting catch-up campaigns, particularly before the introduction of the rubella vaccine [^].
Gavi's funding is crucial for closing critical measles immunity gaps. As a primary funder for immunization activities during measles outbreaks in lower-income countries, Gavi makes significant contributions to the Measles & Rubella Partnership's Outbreak Response Fund [^]. A fully funded Gavi from 2026 onwards is deemed critical for its continued capacity to save lives and control outbreaks through routine immunization programs, preventive campaigns, and emergency responses [^][^]. Ongoing efforts are essential to close immunity gaps through both routine immunization and supplementary preventive campaigns, especially since current coverage rates remain below the 95% threshold required to prevent widespread outbreaks [^][^].
5. What are the 2026 year-end global measles case projections from major epidemiological modeling centers like the IHME and The Lancet?
| Global Measles Cases 2023 | 10.3 million, up 22% from prior year (2023) [^][^] |
|---|---|
| Japan Measles Cases early 2026 | 100 cases, exceeding 2020-2025 levels (early March 2026) [^] |
| US Measles Cases from MMR decline | Over 17,000 annual cases with 1% MMR vaccine decline (US, over 5 years) [^] |
Specific 2026 measles projections from major centers are unavailable. The available research does not contain specific 2026 year-end global measles case projections from the IHME or The Lancet. However, if current trends persist, total global measles cases for 2026 could more than double the record-high numbers observed in 2025 [^]. Measles outbreaks are currently occurring across all regions worldwide, driven by stalled immunization campaigns, shifts in vaccine acceptance, and reductions in public health funding [^][^].
Many countries risk losing or have lost measles elimination status. The United States faces a high risk of losing its measles elimination status by November 2026 due to increasing case counts and sustained transmission [^]. Several other countries have already lost their elimination status, including Canada in late 2025, and six Central Asian and European nations (Armenia, Austria, Azerbaijan, Spain, the United Kingdom, and Uzbekistan) in January 2026. These losses are attributed to continuous transmission and declining vaccination rates [^][^][^].
Global measles cases are rising, with significant regional impacts. In 2023, an estimated 10.3 million people globally were infected with measles, marking a 22% increase from the previous year [^][^]. As of early March 2026, Japan had reported 100 measles cases, a figure exceeding that for the same period in any year from 2020 to 2025 [^]. Furthermore, a modeling analysis from the Yale School of Public Health indicated that a sustained 1% annual decline in MMR vaccine coverage could result in over 17,000 annual measles cases in the US, along with substantial healthcare costs, over the next five years [^].
6. How do the 2026 measles outbreak response strategies and healthcare system capacities of India and Yemen compare?
| India MCV-1 Coverage | 97.8% as of 2024-25 [^][^][^][^][^] |
|---|---|
| India MCV-2 Coverage | 93.3% as of 2024-25 [^][^][^][^][^] |
| Yemen 2026 Measles Cases | 7,140 cases through mid-April 2026 [^][^] |
India's 2026 measles response leverages strong capacity and high vaccination coverage. The strategy emphasizes rapid outbreak investigation, active fever-rash surveillance, and targeted immunization campaigns [^][^][^][^][^]. This approach is supported by a robust Universal Immunisation Programme (UIP) that achieved high vaccination coverage, with MCV-1 at 97.8% and MCV-2 at 93.3% as of 2024-25 [^][^][^][^][^]. India's healthcare system possesses strong institutional capacity for a rapid response to sporadic, localized outbreaks, focusing on measles-rubella elimination [^][^].
Yemen's 2026 measles outbreak response is severely hampered by humanitarian crises. The nation reported 7,140 cases and 36 deaths in government-held areas through mid-April 2026 [^][^]. This situation is exacerbated by a protracted humanitarian emergency, fragmented health governance across territorial divisions, and persistently low vaccination coverage in certain regions [^][^][^][^][^]. Unlike India's focus on elimination of sporadic outbreaks, Yemen faces endemic transmission and significant humanitarian strain, indicating a critical disparity in healthcare system capacities [^][^].
7. What are the release schedules for the CDC's 'Global Measles Outbreaks' report and the WHO's global surveillance data for the rest of 2026?
| CDC Data Update Frequency | Each month [^] |
|---|---|
| WHO Monthly Report Release | By the 3rd Monday of the month [^] |
| WHO Data Reporting Lag | One to two months [^] |
The Centers for Disease Control and Prevention (CDC) provides monthly updates for its "Global Measles Outbreaks" report. These updates compile provisional monthly surveillance data reported to the World Health Organization (WHO) [^]. An example update was cited as "May 15, 2026" [^]. The CDC Measles (Rubeola) counter will be used for tracking measles cases throughout 2026 for specific resolutions, such as on Polymarket [^].
The World Health Organization (WHO) also publishes a monthly report titled "Global Measles and Rubella Monthly Update" [^] . Regional data are typically submitted to WHO headquarters on the first Friday of each month, with the global report aiming for release by the third Monday [^]. It is important to note that WHO's provisional monthly measles and rubella data often experiences a reporting lag of approximately one to two months, meaning the most recent updates may not be complete [^].
8. What impact could political instability and conflict in Sub-Saharan Africa have on vaccination efforts and case reporting throughout 2026?
| Surveillance blind spots expected | Throughout 2026 [^][^][^][^] |
|---|---|
| Sudan sentinel site reporting | Fell to 65% by late 2024 [^][^] |
| Major ongoing disease threat | Measles with sustained upward trend throughout the 2020s [^][^][^] |
Political instability severely impedes vaccination efforts and creates disease surveillance blind spots. Conflict in Sub-Saharan Africa, particularly in Sudan and the Democratic Republic of Congo (DRC), is projected to severely impede vaccination campaigns and lead to "surveillance blind spots" for disease reporting throughout 2026 [^][^][^][^]. This confluence of conflict and disease surveillance is termed a "catastrophic collision," hindering routine immunization and preventing the containment of emerging outbreaks [^][^][^].
Conflict directly destroys health infrastructure and disrupts crucial disease surveillance. The detrimental effects of conflict include the destruction of health infrastructure, displacement of health workers, logistical challenges for cold-chain supply delivery, and administrative obstacles, all of which obstruct vaccination efforts [^][^][^]. These conditions frequently result in data reporting that is incomplete, delayed, or entirely absent; for instance, centralized disease surveillance is structurally impossible in certain parts of eastern DRC in 2026 [^][^][^][^]. Historically, reporting from sentinel sites in Sudan declined to 65% by late 2024 [^][^].
Measles outbreaks are exacerbated, and emerging diseases become harder to contain. Measles remains a significant threat in the region, with outbreaks exacerbated by low vaccination coverage, resurgence of vaccine-preventable diseases due to population displacement and overcrowding, and funding deficiencies, leading to a sustained increase in cases throughout the 2020s [^][^][^]. The "catastrophic collision" further exemplifies its impact on the containment of emerging outbreaks, such as the 2026 Ebola outbreak in the DRC, by inhibiting crucial contact tracing and safe vaccination campaigns in affected areas [^][^][^].
9. What Could Change the Odds
Key Catalysts
Conversely, bearish factors that could reduce case growth include possible emergency federal interventions or intensified vaccination campaigns [^] [^] [^] . 2026: Market Certainty">[^]. These factors contribute to evolving market sentiment, which is reflected in prediction markets actively tracking 2026 measles cases with high-threshold contracts, such as those above 6,000–8,000 cases, based on CDC weekly surveillance updates [^][^].
Key Dates & Catalysts
- Expiration: December 31, 2027
- Closes: January 01, 2027
10. Decision-Flipping Events
- Trigger: Key bullish catalysts for measles case counts include continued low vaccination coverage, international travel from regions with active outbreaks, and the loss of measles-elimination status in several countries [^] [^] [^] .
- Trigger: Conversely, bearish factors that could reduce case growth include possible emergency federal interventions or intensified vaccination campaigns [^] [^] [^] .
- Trigger: These factors contribute to evolving market sentiment, which is reflected in prediction markets actively tracking 2026 measles cases with high-threshold contracts, such as those above 6,000–8,000 cases, based on CDC weekly surveillance updates [^] [^] .
12. Historical Resolutions
Historical Resolutions: 3 markets in this series
Outcomes: 3 resolved YES, 0 resolved NO
Recent resolutions:
- KXMEASLES-26-1750: YES (Jun 09, 2026)
- KXMEASLES-26-1500: YES (Jun 09, 2026)
- KXMEASLES-26-2000: YES (Jun 09, 2026)
Get Real-Time Research Updates
Sign up for early access to live reports, historical data, and AI-powered market insights delivered to your inbox.
